Twitter and become a fan on Facebook.
Investors continued to rotate into domestic stocks seen benefiting from tax cuts, but without higher estimates, the gains could falter.
Jim Cramer is bullish on STMicroelectronics, Intercept Pharmaceuticals, Altria, and Array BioPharma.
Jim Cramer says when this market gets some bad news after its remarkable run, investors have to break out the dominoes to explain the decline.
The San Diego firm is scheduled to present positive preliminary data for two clinical studies of sitravatinib in non-small cell lung cancer at a symposium in Chicago on Friday.